APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Unfractionated Heparin Sodium API

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Unfractionated Heparin Sodium API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173373170319 December 2025196 pages

Choose your research edition.

Industry ResearchUnfractionated Heparin Sodium API Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Unfractionated Heparin Sodium API Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Unfractionated Heparin Sodium API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Unfractionated Heparin Sodium API Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Unfractionated Heparin Sodium API Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Unfractionated Heparin Sodium API market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Unfractionated Heparin Sodium API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Unfractionated Heparin Sodium API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Unfractionated Heparin Sodium API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Unfractionated Heparin Sodium API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Unfractionated Heparin Sodium API include Aspen Oss, Bioibérica, Opocrin, Pfizer, Hebei Changshan Biochemical Pharmaceutical, Cisen Pharmaceutical, Yantai Dongcheng Pharmaceutical, Shenzhen Hepalink Pharmaceutical and Hubei Enoray Biopharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

On the production side, the report examines Unfractionated Heparin Sodium API output, growth rates, and market shares by manufacturer and by region (at regional and country level) for 2021-2026, with forecasts through 2032.

On the consumption side, the report analyzes sales of Unfractionated Heparin Sodium API by region (regional and country level), company, type, and application for 2021-2026 and provides forecasts through 2032.

The report provides an overview of the global Unfractionated Heparin Sodium API market in terms of capacity, output, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Unfractionated Heparin Sodium API and consumption patterns in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Unfractionated Heparin Sodium API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by type and application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Unfractionated Heparin Sodium API market size, projected growth trends, production technologies, key applications, and end-use industries.

Unfractionated Heparin Sodium API Segment by Company

Aspen Oss

Bioibérica

Opocrin

Pfizer

Hebei Changshan Biochemical Pharmaceutical

Cisen Pharmaceutical

Yantai Dongcheng Pharmaceutical

Shenzhen Hepalink Pharmaceutical

Hubei Enoray Biopharmaceutical

Nanjing King-friend Biochemical Pharmaceutical

Qingdao Jiulong Biopharmaceutical

Changzhou Qianhong Biopharma

Dongying Tiandong Pharmaceutical

Nanjing Xinbai Pharmaceutical

Yino Pharma

Unfractionated Heparin Sodium API Segment by Type

USP Grade

EP Grade

Other

Unfractionated Heparin Sodium API Segment by Application

Cardiovascular Disease

Dialysis Anticoagulation

Postoperative Thrombosis Prevention

Other

Unfractionated Heparin Sodium API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Unfractionated Heparin Sodium API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Unfractionated Heparin Sodium API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Unfractionated Heparin Sodium API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Unfractionated Heparin Sodium API market, including product definition, global market growth prospects, production value, capacity, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Unfractionated Heparin Sodium API industry.

Chapter 3: Detailed analysis of Unfractionated Heparin Sodium API market competition landscape. Including Unfractionated Heparin Sodium API manufacturers' output value, output and average price from 2021 to 2026, as well as competition analysis indicators such as origin, product type, application, merger and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 7: Production/Production Value of Unfractionated Heparin Sodium API by region. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 8: Consumption of Unfractionated Heparin Sodium API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Unfractionated Heparin Sodium API Industry Trends Table 2. Unfractionated Heparin Sodium API Industry Drivers Table 3. Unfractionated Heparin Sodium API Industry Opportunities and Challenges Table 4. Unfractionated Heparin Sodium API Industry Restraints Table 5. Global Unfractionated Heparin Sodium API Production Value by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Unfractionated Heparin Sodium API Production Value Share by Manufacturers (2021-2026) Table 7. Global Unfractionated Heparin Sodium API Production by Manufacturers (B units) & (2021-2026) Table 8. Global Unfractionated Heparin Sodium API Production Market Share by Manufacturers Table 9. Global Unfractionated Heparin Sodium API Average Price (USD/B unit) of Manufacturers (2021-2026) Table 10. Global Unfractionated Heparin Sodium API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Unfractionated Heparin Sodium API Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Unfractionated Heparin Sodium API Manufacturers, Product Type & Application Table 13. Global Unfractionated Heparin Sodium API Manufacturers Established Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Unfractionated Heparin Sodium API by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Production Value of 2025) Table 16. Major Manufacturers of USP Grade Table 17. Major Manufacturers of EP Grade Table 18. Major Manufacturers of Other Table 19. Global Unfractionated Heparin Sodium API Production by Type 2021 VS 2025 VS 2032 (B units) Table 20. Global Unfractionated Heparin Sodium API Production by Type (2021-2026) & (B units) Table 21. Global Unfractionated Heparin Sodium API Production by Type (2027-2032) & (B units) Table 22. Global Unfractionated Heparin Sodium API Production Market Share by Type (2021-2026) Table 23. Global Unfractionated Heparin Sodium API Production Market Share by Type (2027-2032) Table 24. Global Unfractionated Heparin Sodium API Production Value by Type 2021 VS 2025 VS 2032 (B units) Table 25. Global Unfractionated Heparin Sodium API Production Value by Type (2021-2026) & (B units) Table 26. Global Unfractionated Heparin Sodium API Production Value by Type (2027-2032) & (B units) Table 27. Global Unfractionated Heparin Sodium API Production Value Market Share by Type (2021-2026) Table 28. Global Unfractionated Heparin Sodium API Production Value Market Share by Type (2027-2032) Table 29. Major Manufacturers of Cardiovascular Disease Table 30. Major Manufacturers of Dialysis Anticoagulation Table 31. Major Manufacturers of Postoperative Thrombosis Prevention Table 32. Major Manufacturers of Other Table 33. Global Unfractionated Heparin Sodium API Production by Application 2021 VS 2025 VS 2032 (B units) Table 34. Global Unfractionated Heparin Sodium API Production by Application (2021-2026) & (B units) Table 35. Global Unfractionated Heparin Sodium API Production by Application (2027-2032) & (B units) Table 36. Global Unfractionated Heparin Sodium API Production Market Share by Application (2021-2026) Table 37. Global Unfractionated Heparin Sodium API Production Market Share by Application (2027-2032) Table 38. Global Unfractionated Heparin Sodium API Production Value by Application 2021 VS 2025 VS 2032 (B units) Table 39. Global Unfractionated Heparin Sodium API Production Value by Application (2021-2026) & (B units) Table 40. Global Unfractionated Heparin Sodium API Production Value by Application (2027-2032) & (B units) Table 41. Global Unfractionated Heparin Sodium API Production Value Market Share by Application (2021-2026) Table 42. Global Unfractionated Heparin Sodium API Production Value Market Share by Application (2027-2032) Table 43. Aspen Oss Company Information Table 44. Aspen Oss Business Overview Table 45. Aspen Oss Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 46. Aspen Oss Unfractionated Heparin Sodium API Product Portfolio Table 47. Aspen Oss Recent Development Table 48. Bioibérica Company Information Table 49. Bioibérica Business Overview Table 50. Bioibérica Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 51. Bioibérica Unfractionated Heparin Sodium API Product Portfolio Table 52. Bioibérica Recent Development Table 53. Opocrin Company Information Table 54. Opocrin Business Overview Table 55. Opocrin Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 56. Opocrin Unfractionated Heparin Sodium API Product Portfolio Table 57. Opocrin Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 61. Pfizer Unfractionated Heparin Sodium API Product Portfolio Table 62. Pfizer Recent Development Table 63. Hebei Changshan Biochemical Pharmaceutical Company Information Table 64. Hebei Changshan Biochemical Pharmaceutical Business Overview Table 65. Hebei Changshan Biochemical Pharmaceutical Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 66. Hebei Changshan Biochemical Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio Table 67. Hebei Changshan Biochemical Pharmaceutical Recent Development Table 68. Cisen Pharmaceutical Company Information Table 69. Cisen Pharmaceutical Business Overview Table 70. Cisen Pharmaceutical Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 71. Cisen Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio Table 72. Cisen Pharmaceutical Recent Development Table 73. Yantai Dongcheng Pharmaceutical Company Information Table 74. Yantai Dongcheng Pharmaceutical Business Overview Table 75. Yantai Dongcheng Pharmaceutical Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 76. Yantai Dongcheng Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio Table 77. Yantai Dongcheng Pharmaceutical Recent Development Table 78. Shenzhen Hepalink Pharmaceutical Company Information Table 79. Shenzhen Hepalink Pharmaceutical Business Overview Table 80. Shenzhen Hepalink Pharmaceutical Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 81. Shenzhen Hepalink Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio Table 82. Shenzhen Hepalink Pharmaceutical Recent Development Table 83. Hubei Enoray Biopharmaceutical Company Information Table 84. Hubei Enoray Biopharmaceutical Business Overview Table 85. Hubei Enoray Biopharmaceutical Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 86. Hubei Enoray Biopharmaceutical Unfractionated Heparin Sodium API Product Portfolio Table 87. Hubei Enoray Biopharmaceutical Recent Development Table 88. Nanjing King-friend Biochemical Pharmaceutical Company Information Table 89. Nanjing King-friend Biochemical Pharmaceutical Business Overview Table 90. Nanjing King-friend Biochemical Pharmaceutical Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 91. Nanjing King-friend Biochemical Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio Table 92. Nanjing King-friend Biochemical Pharmaceutical Recent Development Table 93. Qingdao Jiulong Biopharmaceutical Company Information Table 94. Qingdao Jiulong Biopharmaceutical Business Overview Table 95. Qingdao Jiulong Biopharmaceutical Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 96. Qingdao Jiulong Biopharmaceutical Unfractionated Heparin Sodium API Product Portfolio Table 97. Qingdao Jiulong Biopharmaceutical Recent Development Table 98. Changzhou Qianhong Biopharma Company Information Table 99. Changzhou Qianhong Biopharma Business Overview Table 100. Changzhou Qianhong Biopharma Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 101. Changzhou Qianhong Biopharma Unfractionated Heparin Sodium API Product Portfolio Table 102. Changzhou Qianhong Biopharma Recent Development Table 103. Dongying Tiandong Pharmaceutical Company Information Table 104. Dongying Tiandong Pharmaceutical Business Overview Table 105. Dongying Tiandong Pharmaceutical Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 106. Dongying Tiandong Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio Table 107. Dongying Tiandong Pharmaceutical Recent Development Table 108. Nanjing Xinbai Pharmaceutical Company Information Table 109. Nanjing Xinbai Pharmaceutical Business Overview Table 110. Nanjing Xinbai Pharmaceutical Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 111. Nanjing Xinbai Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio Table 112. Nanjing Xinbai Pharmaceutical Recent Development Table 113. Yino Pharma Company Information Table 114. Yino Pharma Business Overview Table 115. Yino Pharma Unfractionated Heparin Sodium API Production (B units), Value (US$ Million), Price (USD/B unit) and Gross Margin (2021-2026) Table 116. Yino Pharma Unfractionated Heparin Sodium API Product Portfolio Table 117. Yino Pharma Recent Development Table 118. Global Unfractionated Heparin Sodium API Production by Region: 2021 VS 2025 VS 2032 (B units) Table 119. Global Unfractionated Heparin Sodium API Production by Region (2021-2026) & (B units) Table 120. Global Unfractionated Heparin Sodium API Production Market Share by Region (2021-2026) Table 121. Global Unfractionated Heparin Sodium API Production Forecast by Region (2027-2032) & (B units) Table 122. Global Unfractionated Heparin Sodium API Production Market Share Forecast by Region (2027-2032) Table 123. Global Unfractionated Heparin Sodium API Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 124. Global Unfractionated Heparin Sodium API Production Value by Region (2021-2026) & (US$ Million) Table 125. Global Unfractionated Heparin Sodium API Production Value Share by Region (2021-2026) Table 126. Global Unfractionated Heparin Sodium API Production Value by Region (2027-2032) & (US$ Million) Table 127. Global Unfractionated Heparin Sodium API Production Value Share by Region: (2027-2032) & (US$ Million) Table 128. Global Unfractionated Heparin Sodium API Market Average Price (USD/B unit) by Region (2021-2026) Table 129. Global Unfractionated Heparin Sodium API Market Average Price (USD/B unit) by Region (2027-2032) Table 130. Global Unfractionated Heparin Sodium API Consumption by Region: 2021 VS 2025 VS 2032 (B units) Table 131. Global Unfractionated Heparin Sodium API Consumption by Region (2021-2026) & (B units) Table 132. Global Unfractionated Heparin Sodium API Consumption Market Share by Region (2021-2026) Table 133. Global Unfractionated Heparin Sodium API Consumption Forecasted by Region (2027-2032) & (B units) Table 134. Global Unfractionated Heparin Sodium API Consumption Forecasted Market Share by Region (2027-2032) Table 135. North America Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (B units) Table 136. North America Unfractionated Heparin Sodium API Consumption by Country (2021-2026) & (B units) Table 137. North America Unfractionated Heparin Sodium API Consumption by Country (2027-2032) & (B units) Table 138. Europe Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (B units) Table 139. Europe Unfractionated Heparin Sodium API Consumption by Country (2021-2026) & (B units) Table 140. Europe Unfractionated Heparin Sodium API Consumption by Country (2027-2032) & (B units) Table 141. Asia Pacific Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (B units) Table 142. Asia Pacific Unfractionated Heparin Sodium API Consumption by Country (2021-2026) & (B units) Table 143. Asia Pacific Unfractionated Heparin Sodium API Consumption by Country (2027-2032) & (B units) Table 144. South America Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (B units) Table 145. South America Unfractionated Heparin Sodium API Consumption by Country (2021-2026) & (B units) Table 146. South America Unfractionated Heparin Sodium API Consumption by Country (2027-2032) & (B units) Table 147. Middle East & Africa Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (B units) Table 148. Middle East & Africa Unfractionated Heparin Sodium API Consumption by Country (2021-2026) & (B units) Table 149. Middle East & Africa Unfractionated Heparin Sodium API Consumption by Country (2027-2032) & (B units) Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Unfractionated Heparin Sodium API Distributors List Table 153. Unfractionated Heparin Sodium API Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Unfractionated Heparin Sodium API Product Image Figure 2. Global Unfractionated Heparin Sodium API Production Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Unfractionated Heparin Sodium API Production Value (2021-2032) & (US$ Million) Figure 4. Global Unfractionated Heparin Sodium API Production Capacity (2021-2032) & (B units) Figure 5. Global Unfractionated Heparin Sodium API Production (2021-2032) & (B units) Figure 6. Global Unfractionated Heparin Sodium API Average Price (USD/B unit) & (2021-2032) Figure 7. Global Top 5 and 10 Unfractionated Heparin Sodium API Players Market Share by Production Value in 2025 Figure 8. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. USP Grade Image Figure 10. EP Grade Image Figure 11. Other Image Figure 12. Global Unfractionated Heparin Sodium API Production by Type (2021 VS 2025 VS 2032) & (B units) Figure 13. Global Unfractionated Heparin Sodium API Production Market Share 2021 VS 2025 VS 2032 Figure 14. Global Unfractionated Heparin Sodium API Production Market Share by Type (2021-2032) Figure 15. Global Unfractionated Heparin Sodium API Production Value by Type (2021 VS 2025 VS 2032) & (B units) Figure 16. Global Unfractionated Heparin Sodium API Production Value Share 2021 VS 2025 VS 2032 Figure 17. Global Unfractionated Heparin Sodium API Production Value Share by Type (2021-2032) Figure 18. Cardiovascular Disease Image Figure 19. Dialysis Anticoagulation Image Figure 20. Postoperative Thrombosis Prevention Image Figure 21. Other Image Figure 22. Global Unfractionated Heparin Sodium API Production by Application (2021 VS 2025 VS 2032) & (B units) Figure 23. Global Unfractionated Heparin Sodium API Production Market Share 2021 VS 2025 VS 2032 Figure 24. Global Unfractionated Heparin Sodium API Production Market Share by Application (2021-2032) Figure 25. Global Unfractionated Heparin Sodium API Production Value by Application (2021 VS 2025 VS 2032) & (B units) Figure 26. Global Unfractionated Heparin Sodium API Production Value Share 2021 VS 2025 VS 2032 Figure 27. Global Unfractionated Heparin Sodium API Production Value Share by Application (2021-2032) Figure 28. Global Unfractionated Heparin Sodium API Production by Region: 2021 VS 2025 VS 2032 (B units) Figure 29. Global Unfractionated Heparin Sodium API Production Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Unfractionated Heparin Sodium API Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Unfractionated Heparin Sodium API Production Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Unfractionated Heparin Sodium API Production Value (2021-2032) & (US$ Million) Figure 33. Europe Unfractionated Heparin Sodium API Production Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Unfractionated Heparin Sodium API Production Value (2021-2032) & (US$ Million) Figure 35. South America Unfractionated Heparin Sodium API Production Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa Unfractionated Heparin Sodium API Production Value (2021-2032) & (US$ Million) Figure 37. North America Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 38. North America Unfractionated Heparin Sodium API Consumption Market Share by Country (2021-2032) Figure 39. U.S. Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 40. Canada Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 41. Mexico Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 42. Europe Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 43. Europe Unfractionated Heparin Sodium API Consumption Market Share by Country (2021-2032) Figure 44. Germany Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 45. France Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 46. U.K. Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 47. Italy Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 48. Netherlands Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 49. Asia Pacific Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 50. Asia Pacific Unfractionated Heparin Sodium API Consumption Market Share by Country (2021-2032) Figure 51. China Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 52. Japan Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 53. South Korea Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 54. Southeast Asia Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 55. India Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 56. Australia Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 57. South America Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 58. South America Unfractionated Heparin Sodium API Consumption Market Share by Country (2021-2032) Figure 59. Brazil Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 60. Argentina Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 61. Chile Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 62. Colombia Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 63. Middle East & Africa Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 64. Middle East & Africa Unfractionated Heparin Sodium API Consumption Market Share by Country (2021-2032) Figure 65. Egypt Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 66. South Africa Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 67. Israel Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 68. Türkiye Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 69. GCC Countries Unfractionated Heparin Sodium API Consumption and Growth Rate (2021-2032) & (B units) Figure 70. Unfractionated Heparin Sodium API Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Unfractionated Heparin Sodium API Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • USP Grade
  • EP Grade
  • Other
Applications
  • Cardiovascular Disease
  • Dialysis Anticoagulation
  • Postoperative Thrombosis Prevention
  • Other
Companies covered
  • Aspen Oss
  • Bioibérica
  • Opocrin
  • Pfizer
  • Hebei Changshan Biochemical Pharmaceutical
  • Cisen Pharmaceutical
  • Yantai Dongcheng Pharmaceutical
  • Shenzhen Hepalink Pharmaceutical
  • Hubei Enoray Biopharmaceutical
  • Nanjing King-friend Biochemical Pharmaceutical
  • Qingdao Jiulong Biopharmaceutical
  • Changzhou Qianhong Biopharma
  • Dongying Tiandong Pharmaceutical
  • Nanjing Xinbai Pharmaceutical
  • Yino Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Unfractionated Heparin Sodium API Production Value Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Unfractionated Heparin Sodium API Production Capacity Estimates and Forecasts (2021-2032)
  5. 1.2.3 Global Unfractionated Heparin Sodium API Production Estimates and Forecasts (2021-2032)
  6. 1.2.4 Global Unfractionated Heparin Sodium API Market Average Price (2021-2032)
  7. 1.3 Assumptions and Limitations
  8. 1.4 Study Goals and Objectives
2 Global Unfractionated Heparin Sodium API Market Dynamics
  1. 2.1 Unfractionated Heparin Sodium API Industry Trends
  2. 2.2 Unfractionated Heparin Sodium API Industry Drivers
  3. 2.3 Unfractionated Heparin Sodium API Industry Opportunities and Challenges
  4. 2.4 Unfractionated Heparin Sodium API Industry Restraints
3 Unfractionated Heparin Sodium API Market by Manufacturers
  1. 3.1 Global Unfractionated Heparin Sodium API Production Value by Manufacturers (2021-2026)
  2. 3.2 Global Unfractionated Heparin Sodium API Production by Manufacturers (2021-2026)
  3. 3.3 Global Unfractionated Heparin Sodium API Average Price by Manufacturers (2021-2026)
  4. 3.4 Global Unfractionated Heparin Sodium API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Unfractionated Heparin Sodium API Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Unfractionated Heparin Sodium API Manufacturers, Product Type & Application
  7. 3.7 Global Unfractionated Heparin Sodium API Manufacturers Established Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Unfractionated Heparin Sodium API Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Unfractionated Heparin Sodium API Players Market Share by Production Value in 2025
  11. 3.8.3 2025 Unfractionated Heparin Sodium API Tier 1, Tier 2, and Tier 3
4 Unfractionated Heparin Sodium API Market by Type
  1. 4.1 Unfractionated Heparin Sodium API Type Introduction
  2. 4.1.1 USP Grade
  3. 4.1.2 EP Grade
  4. 4.1.3 Other
  5. 4.2 Global Unfractionated Heparin Sodium API Production by Type
  6. 4.2.1 Global Unfractionated Heparin Sodium API Production by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Unfractionated Heparin Sodium API Production by Type (2021-2032)
  8. 4.2.3 Global Unfractionated Heparin Sodium API Production Market Share by Type (2021-2032)
  9. 4.3 Global Unfractionated Heparin Sodium API Production Value by Type
  10. 4.3.1 Global Unfractionated Heparin Sodium API Production Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Unfractionated Heparin Sodium API Production Value by Type (2021-2032)
  12. 4.3.3 Global Unfractionated Heparin Sodium API Production Value Market Share by Type (2021-2032)
5 Unfractionated Heparin Sodium API Market by Application
  1. 5.1 Unfractionated Heparin Sodium API Application Introduction
  2. 5.1.1 Cardiovascular Disease
  3. 5.1.2 Dialysis Anticoagulation
  4. 5.1.3 Postoperative Thrombosis Prevention
  5. 5.1.4 Other
  6. 5.2 Global Unfractionated Heparin Sodium API Production by Application
  7. 5.2.1 Global Unfractionated Heparin Sodium API Production by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Unfractionated Heparin Sodium API Production by Application (2021-2032)
  9. 5.2.3 Global Unfractionated Heparin Sodium API Production Market Share by Application (2021-2032)
  10. 5.3 Global Unfractionated Heparin Sodium API Production Value by Application
  11. 5.3.1 Global Unfractionated Heparin Sodium API Production Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Unfractionated Heparin Sodium API Production Value by Application (2021-2032)
  13. 5.3.3 Global Unfractionated Heparin Sodium API Production Value Market Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Aspen Oss
  2. 6.1.1 Aspen Oss Company Information
  3. 6.1.2 Aspen Oss Business Overview
  4. 6.1.3 Aspen Oss Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  5. 6.1.4 Aspen Oss Unfractionated Heparin Sodium API Product Portfolio
  6. 6.1.5 Aspen Oss Recent Developments
  7. 6.2 Bioibérica
  8. 6.2.1 Bioibérica Company Information
  9. 6.2.2 Bioibérica Business Overview
  10. 6.2.3 Bioibérica Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  11. 6.2.4 Bioibérica Unfractionated Heparin Sodium API Product Portfolio
  12. 6.2.5 Bioibérica Recent Developments
  13. 6.3 Opocrin
  14. 6.3.1 Opocrin Company Information
  15. 6.3.2 Opocrin Business Overview
  16. 6.3.3 Opocrin Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  17. 6.3.4 Opocrin Unfractionated Heparin Sodium API Product Portfolio
  18. 6.3.5 Opocrin Recent Developments
  19. 6.4 Pfizer
  20. 6.4.1 Pfizer Company Information
  21. 6.4.2 Pfizer Business Overview
  22. 6.4.3 Pfizer Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer Unfractionated Heparin Sodium API Product Portfolio
  24. 6.4.5 Pfizer Recent Developments
  25. 6.5 Hebei Changshan Biochemical Pharmaceutical
  26. 6.5.1 Hebei Changshan Biochemical Pharmaceutical Company Information
  27. 6.5.2 Hebei Changshan Biochemical Pharmaceutical Business Overview
  28. 6.5.3 Hebei Changshan Biochemical Pharmaceutical Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  29. 6.5.4 Hebei Changshan Biochemical Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio
  30. 6.5.5 Hebei Changshan Biochemical Pharmaceutical Recent Developments
  31. 6.6 Cisen Pharmaceutical
  32. 6.6.1 Cisen Pharmaceutical Company Information
  33. 6.6.2 Cisen Pharmaceutical Business Overview
  34. 6.6.3 Cisen Pharmaceutical Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  35. 6.6.4 Cisen Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio
  36. 6.6.5 Cisen Pharmaceutical Recent Developments
  37. 6.7 Yantai Dongcheng Pharmaceutical
  38. 6.7.1 Yantai Dongcheng Pharmaceutical Company Information
  39. 6.7.2 Yantai Dongcheng Pharmaceutical Business Overview
  40. 6.7.3 Yantai Dongcheng Pharmaceutical Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  41. 6.7.4 Yantai Dongcheng Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio
  42. 6.7.5 Yantai Dongcheng Pharmaceutical Recent Developments
  43. 6.8 Shenzhen Hepalink Pharmaceutical
  44. 6.8.1 Shenzhen Hepalink Pharmaceutical Company Information
  45. 6.8.2 Shenzhen Hepalink Pharmaceutical Business Overview
  46. 6.8.3 Shenzhen Hepalink Pharmaceutical Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  47. 6.8.4 Shenzhen Hepalink Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio
  48. 6.8.5 Shenzhen Hepalink Pharmaceutical Recent Developments
  49. 6.9 Hubei Enoray Biopharmaceutical
  50. 6.9.1 Hubei Enoray Biopharmaceutical Company Information
  51. 6.9.2 Hubei Enoray Biopharmaceutical Business Overview
  52. 6.9.3 Hubei Enoray Biopharmaceutical Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  53. 6.9.4 Hubei Enoray Biopharmaceutical Unfractionated Heparin Sodium API Product Portfolio
  54. 6.9.5 Hubei Enoray Biopharmaceutical Recent Developments
  55. 6.10 Nanjing King-friend Biochemical Pharmaceutical
  56. 6.10.1 Nanjing King-friend Biochemical Pharmaceutical Company Information
  57. 6.10.2 Nanjing King-friend Biochemical Pharmaceutical Business Overview
  58. 6.10.3 Nanjing King-friend Biochemical Pharmaceutical Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  59. 6.10.4 Nanjing King-friend Biochemical Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio
  60. 6.10.5 Nanjing King-friend Biochemical Pharmaceutical Recent Developments
  61. 6.11 Qingdao Jiulong Biopharmaceutical
  62. 6.11.1 Qingdao Jiulong Biopharmaceutical Company Information
  63. 6.11.2 Qingdao Jiulong Biopharmaceutical Business Overview
  64. 6.11.3 Qingdao Jiulong Biopharmaceutical Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  65. 6.11.4 Qingdao Jiulong Biopharmaceutical Unfractionated Heparin Sodium API Product Portfolio
  66. 6.11.5 Qingdao Jiulong Biopharmaceutical Recent Developments
  67. 6.12 Changzhou Qianhong Biopharma
  68. 6.12.1 Changzhou Qianhong Biopharma Company Information
  69. 6.12.2 Changzhou Qianhong Biopharma Business Overview
  70. 6.12.3 Changzhou Qianhong Biopharma Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  71. 6.12.4 Changzhou Qianhong Biopharma Unfractionated Heparin Sodium API Product Portfolio
  72. 6.12.5 Changzhou Qianhong Biopharma Recent Developments
  73. 6.13 Dongying Tiandong Pharmaceutical
  74. 6.13.1 Dongying Tiandong Pharmaceutical Company Information
  75. 6.13.2 Dongying Tiandong Pharmaceutical Business Overview
  76. 6.13.3 Dongying Tiandong Pharmaceutical Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  77. 6.13.4 Dongying Tiandong Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio
  78. 6.13.5 Dongying Tiandong Pharmaceutical Recent Developments
  79. 6.14 Nanjing Xinbai Pharmaceutical
  80. 6.14.1 Nanjing Xinbai Pharmaceutical Company Information
  81. 6.14.2 Nanjing Xinbai Pharmaceutical Business Overview
  82. 6.14.3 Nanjing Xinbai Pharmaceutical Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  83. 6.14.4 Nanjing Xinbai Pharmaceutical Unfractionated Heparin Sodium API Product Portfolio
  84. 6.14.5 Nanjing Xinbai Pharmaceutical Recent Developments
  85. 6.15 Yino Pharma
  86. 6.15.1 Yino Pharma Company Information
  87. 6.15.2 Yino Pharma Business Overview
  88. 6.15.3 Yino Pharma Unfractionated Heparin Sodium API Production, Value and Gross Margin (2021-2026)
  89. 6.15.4 Yino Pharma Unfractionated Heparin Sodium API Product Portfolio
  90. 6.15.5 Yino Pharma Recent Developments
7 Global Unfractionated Heparin Sodium API Production by Region
  1. 7.1 Global Unfractionated Heparin Sodium API Production by Region: 2021 VS 2025 VS 2032
  2. 7.2 Global Unfractionated Heparin Sodium API Production by Region (2021-2032)
  3. 7.2.1 Global Unfractionated Heparin Sodium API Production by Region (2021-2026)
  4. 7.2.2 Global Unfractionated Heparin Sodium API Production Forecast by Region (2027-2032)
  5. 7.3 Global Unfractionated Heparin Sodium API Production by Region: 2021 VS 2025 VS 2032
  6. 7.4 Global Unfractionated Heparin Sodium API Production Value by Region (2021-2032)
  7. 7.4.1 Global Unfractionated Heparin Sodium API Production Value by Region (2021-2026)
  8. 7.4.2 Global Unfractionated Heparin Sodium API Production Value by Region (2027-2032)
  9. 7.5 Global Unfractionated Heparin Sodium API Market Price Analysis by Region (2021-2032)
  10. 7.6 Regional Production Value Trends (2021-2032)
  11. 7.6.1 North America Unfractionated Heparin Sodium API Production Value (2021-2032)
  12. 7.6.2 Europe Unfractionated Heparin Sodium API Production Value (2021-2032)
  13. 7.6.3 Asia-Pacific Unfractionated Heparin Sodium API Production Value (2021-2032)
  14. 7.6.4 South America Unfractionated Heparin Sodium API Production Value (2021-2032)
  15. 7.6.5 Middle East & Africa Unfractionated Heparin Sodium API Production Value (2021-2032)
8 Global Unfractionated Heparin Sodium API Consumption by Region
  1. 8.1 Global Unfractionated Heparin Sodium API Consumption by Region: 2021 VS 2025 VS 2032
  2. 8.2 Global Unfractionated Heparin Sodium API Consumption by Region (2021-2032)
  3. 8.2.1 Global Unfractionated Heparin Sodium API Consumption by Region (2021-2026)
  4. 8.2.2 Global Unfractionated Heparin Sodium API Consumption by Region (2027-2032)
  5. 8.3 North America
  6. 8.3.1 North America Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 8.3.2 North America Unfractionated Heparin Sodium API Consumption by Country (2021-2032)
  8. 8.3.3 U.S.
  9. 8.3.4 Canada
  10. 8.3.5 Mexico
  11. 8.4 Europe
  12. 8.4.1 Europe Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 8.4.2 Europe Unfractionated Heparin Sodium API Consumption by Country (2021-2032)
  14. 8.4.3 Germany
  15. 8.4.4 France
  16. 8.4.5 U.K.
  17. 8.4.6 Italy
  18. 8.4.7 Netherlands
  19. 8.5 Asia Pacific
  20. 8.5.1 Asia Pacific Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 8.5.2 Asia Pacific Unfractionated Heparin Sodium API Consumption by Country (2021-2032)
  22. 8.5.3 China
  23. 8.5.4 Japan
  24. 8.5.5 South Korea
  25. 8.5.6 Southeast Asia
  26. 8.5.7 India
  27. 8.5.8 Australia
  28. 8.6 South America
  29. 8.6.1 South America Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 8.6.2 South America Unfractionated Heparin Sodium API Consumption by Country (2021-2032)
  31. 8.6.3 Brazil
  32. 8.6.4 Argentina
  33. 8.6.5 Chile
  34. 8.6.6 Colombia
  35. 8.7 Middle East & Africa
  36. 8.7.1 Middle East & Africa Unfractionated Heparin Sodium API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  37. 8.7.2 Middle East & Africa Unfractionated Heparin Sodium API Consumption by Country (2021-2032)
  38. 8.7.3 Egypt
  39. 8.7.4 South Africa
  40. 8.7.5 Israel
  41. 8.7.6 Türkiye
  42. 8.7.7 GCC Countries
9 Value Chain and Sales Channels Analysis
  1. 9.1 Unfractionated Heparin Sodium API Value Chain Analysis
  2. 9.1.1 Unfractionated Heparin Sodium API Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Unfractionated Heparin Sodium API Production Mode & Process
  6. 9.2 Unfractionated Heparin Sodium API Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Unfractionated Heparin Sodium API Distributors
  9. 9.2.3 Unfractionated Heparin Sodium API Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst